In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
Keywords: AVIFAVIR; COVID-19; SARS-CoV-2; favipiravir.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.